Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031957.pdf
0001104659-15-031957.rtf
0001104659-15-031957.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031953.pdf
0001104659-15-031953.rtf
0001104659-15-031953.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031954.pdf
0001104659-15-031954.rtf
0001104659-15-031954.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031951.pdf
0001104659-15-031951.rtf
0001104659-15-031951.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-031952.pdf
0001104659-15-031952.rtf
0001104659-15-031952.xls
424B4

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3

 View HTML
0001047469-15-004205.pdf
0001047469-15-004205.rtf
0001047469-15-004205.xls
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-15-032381.pdf
0001104659-15-032381.rtf
0001104659-15-032381.xls
CERTNAS

CERTNAS

 View HTML
9999999997-15-008888.pdf
9999999997-15-008888.rtf
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

 View HTML
0001104659-15-031752.pdf
0001104659-15-031752.rtf
0001104659-15-031752.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001012975-15-000312.pdf
0001012975-15-000312.rtf
0001012975-15-000312.xls